TORC1 and TORC2 converge to regulate the SAGA co-activator in response to nutrient availability

被引:31
|
作者
Laboucarie, Thomas [1 ]
Detilleux, Dylane [1 ]
Rodriguez-Mias, Ricard A. [2 ]
Faux, Celine [1 ]
Romeo, Yves [1 ,5 ]
Franz-Wachtel, Mirita [3 ]
Krug, Karsten [3 ]
Macek, Boris [3 ]
Villen, Judit [2 ]
Petersen, Janni [4 ]
Helmlinger, Dominique [1 ]
机构
[1] Univ Montpellier, CNRS, CRBM, Montpellier, France
[2] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA
[3] Proteome Ctr Tubingen, Tubingen, Germany
[4] Flinders Univ S Australia, Sch Med, Flinders Ctr Innovat Canc, Fac Hlth Sci, Adelaide, SA, Australia
[5] Univ Toulouse Paul Sabatier, CNRS, UMR 5099, Lab Biol Mol Eucaryote, Toulouse, France
关键词
differentiation; fission yeast; SAGA; signal transduction; TOR; transcription; PROTEIN PHOSPHATASE 2A; CELL-GROWTH CONTROL; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; SEXUAL-DIFFERENTIATION; TRANSCRIPTION FACTOR; SACCHAROMYCES-CEREVISIAE; BINDING PROTEIN; NITROGEN STARVATION; CONFORMATIONAL FLEXIBILITY;
D O I
10.15252/embr.201744942
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Gene expression regulation is essential for cells to adapt to changes in their environment. Co-activator complexes have well-established roles in transcriptional regulation, but less is known about how they sense and respond to signaling cues. We have previously shown that, in fission yeast, one such co-activator, the SAGA complex, controls gene expression and the switch from proliferation to differentiation in response to nutrient availability. Here, using a combination of genetic, biochemical, and proteomic approaches, we show that SAGA responds to nutrients through the differential phosphorylation of its Taf12 component, downstream of both the TORC1 and TORC2 pathways. Taf12 phosphorylation increases early upon starvation and is controlled by the opposing activities of the PP2A phosphatase, which is activated by TORC1, and the TORC2-activated Gad8(AKT) kinase. Mutational analyses suggest that Taf12 phosphorylation prevents cells from committing to differentiation until starvation reaches a critical level. Overall, our work reveals that SAGA is a direct target of nutrient-sensing pathways and has uncovered a mechanism by which TORC1 and TORC2 converge to control gene expression and cell fate decisions.
引用
收藏
页码:2197 / 2218
页数:22
相关论文
共 50 条
  • [41] Whi2 is a conserved negative regulator of TORC1 in response to low amino acids
    Chen, Xianghui
    Wang, Guiqin
    Zhang, Yu
    Dayhoff-Brannigan, Margaret
    Diny, Nicola L.
    Zhao, Mingjun
    He, Ge
    Sing, Cierra N.
    Metz, Kyle A.
    Stolp, Zachary D.
    Aouacheria, Abdel
    Cheng, Wen-Chih
    Hardwick, J. Marie
    Teng, Xinchen
    PLOS GENETICS, 2018, 14 (08):
  • [42] Differentiation of PI3K/Akt/mTOR inhibition in cancer models using dual dissociative TORC1/TORC2 (P529), single dissociative TORC1 (rapalogs) and catalytic inhibitors (PI3K/Akt, PI3K/mTOR)
    Sherris, David
    Dennis, Philip A.
    Wilson, Willie, III
    Kawabata, Shigeru
    Yu, Chunrong
    Gravina, Giovanni Luca
    Mancini, Andrea
    Festuccia, Claudio
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
  • [43] The fission yeast FLCN/FNIP complex augments TORC1 repression or activation in response to amino acid (AA) availability
    Calvo, Isabel A.
    Sharma, Shalini
    Paulo, Joao A.
    Gulka, Alexander O. D.
    Boeszoermenyi, Andras
    Zhang, Jingyu
    Lombana, Jose M.
    Palmieri, Christina M.
    Laviolette, Laura A.
    Arthanari, Haribabu
    Iliopoulos, Othon
    Gygi, Steven P.
    Motamedi, Mo
    ISCIENCE, 2021, 24 (11)
  • [44] The TORC1/TORC2 inhibitor, palomid 529 (P529), reduces tumor growth and sensitizes to chemotherapy and radiotherapy aggressive hormone refractory prostate cancer cells both in vitro and in vivo
    Festuccia, C.
    Gravina, G. L.
    Marampon, F.
    Biordi, L.
    Sherris, D.
    Tombolini, V.
    EJC SUPPLEMENTS, 2010, 8 (07): : 26 - 26
  • [45] Regulation of TORC1 in Response to Amino Acid Starvation via Lysosomal Recruitment of TSC2
    Demetriades, Constantinos
    Doumpas, Nikolaos
    Teleman, Aurelio A.
    CELL, 2014, 156 (04) : 786 - 799
  • [46] First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma
    Tan, D. S.
    Dumez, H.
    Olmos, D.
    Sandhu, S. K.
    Hoeben, A.
    Stephens, A. W.
    Poondru, S.
    Gedrich, R.
    Kaye, S. B.
    Schoffski, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] THE TORC1/TORC2 INHIBITOR, PALOMID 529 (P529), REDUCES TUMOR GROWTH AND SENSITIZES AGGRESSIVE HORMONE-REFRACTORY PROSTATE CANCER CELLS TO CHEMOTHERAPY AND RADIOTHERAPY BOTH IN VITRO AND IN VIVO
    Festuccia, Claudio
    Gravina, Giovanni Luca
    Marampon, Francesco
    Biordi, Leda
    Sherris, David
    Tombolini, Vincenzo
    ANTICANCER RESEARCH, 2011, 31 (05) : 1822 - 1822
  • [48] Protein kinase A regulates the Ras, Rap1 and TORC2 pathways in response to the chemoattractant cAMP in Dictyostelium
    Scavello, Margarethakay
    Petlick, Alexandra R.
    Ramesh, Ramya
    Thompson, Valery F.
    Lotfi, Pouya
    Charest, Pascale G.
    JOURNAL OF CELL SCIENCE, 2017, 130 (09) : 1545 - 1558
  • [49] The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models
    Gravina, Giovanni Luca
    Mancini, Andrea
    Colapietro, Alessandro
    Delle Monache, Simona
    Sferra, Roberta
    Pompili, Simona
    Vitale, Flora
    Martellucci, Stefano
    Marampon, Francesco
    Mattei, Vincenzo
    Biordi, Leda
    Sherris, David
    Festuccia, Claudio
    CANCERS, 2019, 11 (10)
  • [50] A Phase 1 safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with malignant glioma
    Wen, Patrick V.
    Omuro, Antonio M.
    Batchelor, Tracy T.
    Lai, Albert
    Mellinghoff, Ingo K.
    Nghiemphu, Leia
    Norden, Andrew
    Gendreau, Steven B.
    Laird, A. Douglas
    Nguyen, Linh
    Cloughesy, Timothy
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)